Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept plus FOLFIRI as second-line therapy in advanced colorectal cancer
KCT0004757Phase 4Recruiting
- Sponsor
- Yonsei University Health System
- Start
- May 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in metastatic colon cancer (mCRC), sponsored by Yonsei University Health System. Started May 2020; status: recruiting.
02
Drugs
aflibercept
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on KCT0004757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004757.